Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

7.7%

1 terminated/withdrawn out of 13 trials

Success Rate

92.3%

+5.8% vs industry average

Late-Stage Pipeline

23%

3 trials in Phase 3/4

Results Transparency

8%

1 of 12 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
4(30.8%)
Phase 2
4(30.8%)
Phase 3
3(23.1%)
N/A
2(15.4%)
13Total
Phase 1(4)
Phase 2(4)
Phase 3(3)
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (13)

Showing 13 of 13 trials
NCT03163641Not ApplicableCompleted

Safety and Effectiveness of OBG vs.a Bandage Contact Lens for Large Corneal Epithelial Defects in Patients Post-PRK.

Role: lead

NCT03938883Not ApplicableCompleted

Ocular Bandage Gel (OBG) Pivotal Trial in Patients Undergoing Photorefractive Keratectomy ("PRK")

Role: lead

NCT01602068Phase 2Completed

Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Delivery Prior to Implantation of a Posterior Chamber IOL

Role: lead

NCT02517619Phase 3Completed

Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis

Role: lead

NCT03180255Phase 2Completed

Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery

Role: lead

NCT02644694Phase 1Completed

PK Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Undergoing Vitrectomy

Role: lead

NCT02571556Phase 1Completed

OPEN-LABEL, MULTI-CENTER, PHASE 1b/2a CLINICAL TRIAL DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF IONTOPHORETIC DEXAMETHASONE PHOSPHATE OPHTHALMIC SOLUTION IN PATIENTS HAVING UNDERGONE CATARACT SURGERY WITH IMPLANTATION OF A POSTERIOR CHAMBER INTRAOCULAR LENS (IOL)

Role: lead

NCT02485249Phase 1Terminated

Open-label, Multli-center, Phase 1b/2a Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients With Macular Edema

Role: lead

NCT01505088Phase 3Completed

Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis

Role: lead

NCT01129856Phase 3Completed

Safety and Efficacy Study of EGP-437 (Dexamethasone Phosphate Formulated for Ocular Iontophoresis) to Treat Dry Eye

Role: lead

NCT00694135Phase 2Completed

Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis

Role: lead

NCT00765804Phase 2Completed

Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye

Role: lead

NCT00698425Phase 1Completed

Safety and Tolerability Study of Transscleral Iontophoresis by the EyeGate® II Drug Delivery Device System

Role: lead

All 13 trials loaded